Abbvie Inc Stock Today
| ABBV Stock | USD 204.14 0.06 0.03% |
PerformanceGood
| Odds Of DistressLow
|
AbbVie is selling for under 204.14 as of the 25th of February 2025; that is 0.03 percent increase since the beginning of the trading day. The stock's lowest day price was 202.35. AbbVie has less than a 10 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Note, on February 11, 2025, Representative Jared Moskowitz of US Congress acquired under $15k worth of AbbVie Inc's common stock.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Abbvie operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 1.77 B outstanding shares of which 18.93 M shares are presently shorted by private and institutional investors with about 3.11 trading days to cover. More on AbbVie Inc
Moving against AbbVie Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
AbbVie Stock Highlights
| CEO Director | Robert CPA |
| Thematic Ideas | (View all Themes) |
| Old Names | [AbbVie Inc, AbbVie Inc] |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, SP 500 Index, SP 100 Index, SP 100, Dow Jones Biotechnology, ARCA Institutional, Giant Impact, Cannabis, Macroaxis Index, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors) |
AbbVie Inc (ABBV) is traded on New York Stock Exchange in USA. It is located in 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 and employs 55,000 people. AbbVie is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 360.27 B. AbbVie Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.77 B outstanding shares of which 18.93 M shares are presently shorted by private and institutional investors with about 3.11 trading days to cover.
AbbVie Inc currently holds about 11.88 B in cash with 18.81 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.72.
Check AbbVie Probability Of Bankruptcy
Ownership AllocationAbbVie holds a total of 1.77 Billion outstanding shares. The majority of AbbVie Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in AbbVie Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in AbbVie. Please pay attention to any change in the institutional holdings of AbbVie Inc as this could imply that something significant has changed or is about to change at the company. On February 11, 2025, Representative Jared Moskowitz of US Congress acquired under $15k worth of AbbVie Inc's common stock.
Check AbbVie Ownership Details
AbbVie Inc Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. AbbVie market risk premium is the additional return an investor will receive from holding AbbVie long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.1174 | |||
| Jensen Alpha | 0.1988 | |||
| Total Risk Alpha | 0.1892 | |||
| Sortino Ratio | 0.1866 |
AbbVie Stock Against Markets
AbbVie Corporate Directors
| Brett Hart | Independent Director | Profile | |
| Roxanne Austin | Independent Director | Profile | |
| Edward Rapp | Independent Director | Profile | |
| Frederick Waddell | Independent Director | Profile |
Already Invested in AbbVie Inc?
The danger of trading AbbVie Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AbbVie is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AbbVie. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AbbVie Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.